Capstone Investment Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.62M Buy
98,546
+88,827
+914% +$4.21M 0.01% 493
2025
Q4
$495K Buy
9,719
+6,034
+164% +$309K ﹤0.01% 1152
2025
Q3
$204K Sell
3,685
-146,315
-98% -$8.56M ﹤0.01% 1820
2025
Q2
$10.4M Buy
+150,000
New +$10.2M 0.03% 239

Other funds holding NVO

Capstone Investment Advisors's NVO Position: Q1 2026 in Review

Capstone Investment Advisors increased its Novo Nordisk (NVO) stake by 914% in Q1 2026, buying an estimated $4.21M and bringing the position to 98,546 shares worth $3.62M. The position accounts for 0.01% of the portfolio, ranked #493.

Capstone Investment Advisors first reported a position in NVO in Q2 2025 and has held it in 4 quarters since. The position peaked at $10.4M in Q2 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Capstone Investment Advisors held 98,546 shares of Novo Nordisk worth $3.62M as of Q1 2026.
  • Capstone Investment Advisors bought 88,827 Novo Nordisk shares in Q1 2026, an estimated $4.21M.
  • Novo Nordisk made up 0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #493 holding.
  • Capstone Investment Advisors first reported a position in Novo Nordisk in Q2 2025 and has held it in 4 quarters since.
  • Capstone Investment Advisors's Novo Nordisk position peaked at $10.4M in Q2 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.